Doxy-PEP—a single dose of doxycycline taken after sex—has strong evidence for preventing bacterial STIs in gay and bisexual men and transgender women, but the one major trial in cisgender women did not show the same benefit. Because of that, U.S. guidance does not broadly recommend it for women. Below is what the studies actually found.
doxycycline, within 72 hours after sex
syphilis, chlamydia, some gonorrhea
MSM & trans women with a recent bacterial STI
evidence still limited for others
| Item | Value |
|---|---|
| Dose | 200 mg — doxycycline, within 72 hours after sex |
| Reduces | bacterial STIs — syphilis, chlamydia, some gonorrhea |
| For | specific groups — MSM & trans women with a recent bacterial STI |
| Not for | everyone — evidence still limited for others |
What is Doxy-PEP and how does it work?
Doxy-PEP stands for doxycycline post-exposure prophylaxis. It's a single dose of the antibiotic doxycycline taken after condomless sex to lower the risk of catching certain bacterial sexually transmitted infections CDC. Doxycycline reaches the tissues where bacteria first take hold and clears them before an infection can establish.
It works only against bacteria. Doxy-PEP targets the three reportable bacterial STIs—syphilis, chlamydia, and gonorrhea—and does nothing against HIV or other viral infections like herpes or HPV. It's a narrow tool, a single pill kept on hand and swallowed after sex, not a daily medication.
How well does Doxy-PEP work—and what do the studies show for women?
In the populations where it's been studied most, doxy-PEP reduces the risk of syphilis and chlamydia, and in some trials gonorrhea, though the effect on gonorrhea has been less consistent across studies. That inconsistency matters because gonorrhea is increasingly resistant to antibiotics, including the tetracycline class doxycycline belongs to.
The largest trial that enrolled cisgender women did not find a protective benefit, and that's why current guidance treats women differently. Researchers point to two likely explanations. One is adherence—taking the pill reliably within the recommended window after each exposure. The other is biological: drug levels in vaginal and cervical tissue may not reach the same protective concentrations seen in rectal tissue, which could blunt the effect even when someone takes the pill correctly.
The evidence isn't there yet for women. CDC states that there is not enough evidence to weigh the benefits and harms of doxy-PEP for groups outside the studied populations, including cisgender women, so it is not broadly recommended for everyone CDC MMWR, 2024. That isn't the same as saying it can't work; the data don't currently support recommending it across the board.
Who is it recommended for, and how is it taken?
CDC guidance is for clinicians to discuss doxy-PEP with gay and bisexual men and transgender women who have had at least one bacterial STI—gonorrhea, chlamydia, or syphilis—in the past 12 months. A recent infection is the practical marker of higher ongoing risk, where the benefit is most likely to outweigh concerns about antibiotic use.
The standard dose is 200 mg of doxycycline taken as soon as possible, and within 72 hours, after sex. The guidance also caps how often you take it: no more than that amount in any 24-hour period, so multiple encounters in a short span don't mean stacking doses.
- Keep the pills on hand so you're not scrambling after the fact.
- Take a single dose as soon as possible after condomless sex, ideally within the 72-hour window.
- Don't exceed the maximum amount in any 24-hour period, even after multiple encounters.
- Pair it with regular STI screening rather than treating it as a substitute for testing.
For cisgender women, talk it through with a clinician rather than assume it'll protect you the way it does in studied groups. Some providers may consider it case by case, but it's not a routine recommendation. You can read more about the medication itself on our doxypep overview.
How much does Doxy-PEP cost and how do you get it?
Doxy-PEP requires a prescription, so the path is a conversation with a clinician—a primary-care provider, a sexual-health clinic, or a telehealth service that handles STI prevention. Doxycycline itself is a long-established generic antibiotic, which keeps it among the more affordable prescription options, though your out-of-pocket cost depends on insurance and pharmacy. Because it's prescribed for specific higher-risk groups rather than handed to everyone, a provider will usually review your recent STI history before writing it.
What Doxy-PEP does NOT protect against
Doxy-PEP is a backstop, and people can read too much into it. It does nothing against HIV, herpes, HPV, hepatitis, or any other viral infection. Its effect on gonorrhea is uneven, and rising tetracycline resistance is a real limitation. It also doesn't prevent pregnancy.
Because long-term effects on antibiotic resistance aren't yet fully understood, CDC continues to monitor resistance as doxy-PEP use spreads. Wider antibiotic exposure could drive resistance in the very bacteria you're trying to prevent, so it's targeted to people most likely to benefit rather than recommended for everyone.
How Doxy-PEP fits with condoms, vaccines, and testing
Doxy-PEP works best as one layer in a fuller prevention plan. Condoms still reduce exposure to the viruses doxy-PEP can't touch. Vaccines cover HPV and hepatitis B. Regular screening catches infections that slip through any single method.
| Tool | What it covers | Key limit |
|---|---|---|
| Doxy-PEP | Reduces syphilis and chlamydia; gonorrhea less consistently | Bacteria only; not recommended broadly for women |
| Condoms | Bacterial and viral STIs, plus pregnancy | Only works when used every time, correctly |
| Vaccines | HPV and hepatitis B | No coverage for chlamydia, gonorrhea, syphilis, or HIV |
| Routine testing | Detects existing infections so they're treated early | Doesn't prevent—it finds |
If you're sexually active, make screening a habit regardless of whether doxy-PEP is on the table for you—you can get tested through a clinic or at-home service. And if you've had a specific exposure, our guide on when to test after exposure explains how soon a test can reliably pick up each infection.
When should you talk to a clinician?
Bring up doxy-PEP if you've had a recent bacterial STI and want to discuss whether prophylaxis fits your situation. For cisgender women specifically, that conversation should include the trial findings, and it's reasonable to ask your provider directly what the evidence does and doesn't support for you. Also see a clinician if you develop symptoms like unusual discharge, pelvic or genital pain, sores, or burning with urination, since those need testing and treatment, not prevention. Learn more about one of the infections doxy-PEP targets in our chlamydia overview.